PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
辉瑞(US:PFE) Prnewswire·2025-10-18 22:30Accessibility StatementSkip Navigation TOKYO and NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced positive results from the pivotal Phase 3 EV-303 clinical trial (also known as KEYNOTE-905) for PADCEVÂ (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with KEYTRUDAÂ (pembrolizumab), a PD-1 inhibitor. The study evaluated the combination in patients with muscle-inva ...